Can a 'Universal' cancer target outsmart resistant blood cancers?
Disease control
Not yet recruiting
This early-phase trial is testing an experimental drug called VTRU200 in people with certain blood cancers that have returned or not responded to standard treatments, including acute myeloid leukemia, high-risk myelodysplastic syndromes, and diffuse large B-cell lymphoma after CA…
Phase: PHASE1, PHASE2 • Sponsor: Vitruviae • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC